Filing identity and reporting period
Important mismatch: The supplied filing is NeoStem, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2012—not a Lisata Therapeutics, Inc. filing for 2011 Q3. The summary below reflects the filing text provided.
NeoStem described its continuing business as cell therapy, combining contract development and manufacturing services (CDMO) with cell-therapy product development and cell collection, processing, and storage services. Its China operations were reported as discontinued operations; the sale of its 51% interest in Suzhou Erye closed on November 13, 2012, after quarter-end.
Financial performance and position
| Metric | Three months ended September 30, 2012 | Nine months ended September 30, 2012 | Comparable 2011 period |
|---|---|---|---|
| Continuing revenue | $4.43 million | $11.58 million | $2.18 million and $5.84 million |
| Gross profit | $0.69 million; 15.5% margin | $2.14 million; 18.5% margin | $0.29 million and $0.50 million; margins 13.1% and 8.6% |
| Operating expenses | $8.78 million | $24.58 million | $7.52 million and $26.95 million |
| Operating loss | $(8.09) million | $(22.44) million | $(7.23) million and $(26.45) million |
| Net loss from continuing operations | $(8.55) million | $(23.77) million | $(6.57) million and $(26.94) million |
| Net loss, including discontinued operations | $(8.40) million | $(51.03) million | $(7.33) million and $(27.73) million |
| Loss per common share | $(0.06) | $(0.30) | $(0.08) and $(0.35) |
Quarterly continuing revenue more than doubled year over year, driven principally by clinical services. Nine-month revenue rose 98%. Gross margins improved, but the business remained loss-making; quarterly research and development expense increased 84% year over year, largely reflecting the AMR-001 Phase 2 trial.
At September 30, cash and cash equivalents attributable to continuing operations were $5.39 million; working capital was negative $2.5 million. Continuing-operations cash used in operating activities was $16.40 million for the first nine months, compared with $15.96 million in 2011. Continuing-operations financing provided $15.62 million, while investing provided $2.53 million, including $2.73 million of advance Erye sale proceeds. Consolidated cash, including discontinued operations, was $16.18 million.
Balance-sheet total assets were $128.81 million and total equity was $53.71 million. Current liabilities totaled $50.44 million, including $3.49 million of current mortgages and $0.14 million of current notes payable. The filing reports $0.18 million of notes payable in total. Both mortgages were classified as current; covenant waivers had been obtained for specified prior measurement dates. Series E preferred stock was reported as redeemable securities of $2.72 million at quarter-end.
Material changes and unusual items
- NeoStem exited its China regenerative-medicine operation and agreed to sell its 51% Erye interest. The Erye business generated $57.25 million of revenue in the first nine months but had a $25.54 million discontinued-operations loss, including a $31.17 million asset impairment. These amounts are included in discontinued operations, not continuing revenue.
- Continuing operations’ nine-month loss improved from $26.94 million to $23.77 million, while total net loss worsened from $27.73 million to $51.03 million, mainly because of discontinued-operation losses and impairment.
- In October 2012, the company redeemed all remaining Series E preferred shares for approximately $3.4 million in cash, partly funded by release of $2.5 million held in escrow. The Erye sale subsequently closed for $12.28 million cash plus return of 1.04 million common shares and cancellation of 1.17 million options and 640,000 warrants.
- Common shares outstanding increased from 109.33 million at December 31, 2011 to 155.14 million at September 30, 2012, reflecting equity issuance and warrant exercises. The cover reports 159.41 million shares outstanding as of November 13, 2012.
- Warrant-exercise inducements and preferred-stock-related charges affected results. Nine-month share-based compensation was $5.47 million; warrant inducements were $1.01 million in the nine-month common-shareholder loss calculation.
Outlook, risks, and contingencies
Management anticipated further capital needs to develop cell therapies, fund AMR-001, and grow PCT, including possible European expansion. The 160-patient AMR-001 Phase 2 trial was expected to cost approximately $16 million over its first two years and up to $21 million over five years, including manufacturing. The filing provides no formal revenue or earnings guidance. Management cited revenue growth and existing cash, financing, warrant exercises, equity lines, debt, and asset sales as potential liquidity sources, while cautioning that financing may not be available on acceptable terms or at all. Additional equity could dilute shareholders; insufficient capital could delay or stop development and expansion.
Key risks include sustained operating losses and cash outflows, dependence on external capital, clinical-trial enrollment and outcomes, regulatory approvals, commercialization and market acceptance, competition, and integration and growth of acquired businesses. Erye had approximately RMB 17.9 million (about $2.8 million) frozen in bank accounts in connection with copyright litigation; other Chinese regulatory and legal matters were also described. PCT was not in compliance with mortgage financial covenants at cited measurement dates and obtained lender waivers.
Management concluded disclosure controls and procedures were not effective because of an unremediated material weakness associated with Erye’s accounting controls, including insufficient qualified personnel, segregation-of-duties gaps, incomplete long-term-asset records, Chinese tax-code expertise, and transaction audit trails. The company reported steps to strengthen controls; Erye’s subsequent divestiture does not itself establish that the weakness was remediated before closing.
Important facts for investors to verify
- Confirm the intended issuer and period: the source is NeoStem’s 2012 Q3 10-Q, not the Lisata 2011 Q3 filing stated in the request metadata.
- Review subsequent filings for the completed Erye sale, net proceeds received, final accounting for discontinued operations, and any remaining China-related obligations or contingencies.
- Assess liquidity after the October preferred-stock redemption and subsequent financings, alongside continuing operating cash burn and the AMR-001 trial’s expected funding needs.
- Check progress and costs of the AMR-001 Phase 2 trial, including enrollment, milestones, and any updated development plans.
- Review remediation of the disclosed material weakness and the status of mortgage covenant compliance and waivers.
- Assess dilution and potential overhang from equity offerings, Aspire Capital purchases, warrants, options, and other outstanding securities.